Human coronary atherosclerosis modulates cardiac natriuretic peptide release

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 258-264

  Barbato, Emanuele ^a   Rubattu, Speranza ^b,c   Bartunek, Jozef ^a   Berni, Andrea ^b   Sarno, Giovanna ^a   Vanderheyden, Marc ^a   Delrue, Leen ^a   Zardi, Domenico ^b   Pace, Biagio ^b   De Bruyne, Bernard ^a   Wijns, William ^a   Volpe, Massimo ^b,c  

^a Cardiovascular Center OLV Aalst   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Angina; Atherosclerosis; Endothelium; Natriuretic peptides; Vasoconstriction

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NATRIURETIC FACTOR; RENIN INHIBITOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORONARY FLOW RESERVE; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

ATRIAL NATRIURETIC FACTOR; COLD TEMPERATURE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX;

EID: 68949211258     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.01.033     Document Type: Article

References (49)

1. Stary H.C., Chandler A.B., Dinsmore R.E., et al. Definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 92 (1995) 1355-1374
2. Marumo T., Nakaki T., Hishikawa K., et al. Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3′ 5′-monophosphate elevation in vascular smooth muscle cells. Endocrinology 136 (1995) 2135-2142
3. Kariya K., Kawahara Y., Araki S., Fukuzaki H., and Takai Y. Anti-proliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 80 (1989) 143-147
4. Itoh H., Pratt R.E., Ohno M., and Dzau V.J. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 19 (1992) 758-761
5. Casco V.H., Veinot J.P., de Bold M.L.K., et al. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 50 (2002) 799-809
6. Nabel E.G., Ganz P., Gordon J.B., Alexander R.W., and Selwyn A.P. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 77 (1988) 43-52
7. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
8. Pijls N.H., De Bruyne B., Peels K., et al. Measurement of fractional flow reserve to assess the functional severity of coronary artery stenoses. N Engl J Med 334 26 (1996) 1703-1708
9. European Study group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 19 (1998) 990-1003
10. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19' 7 (1992) 1550-1558
11. Fischer J.J., Samady H., McPherson J.A., et al. Comparison between visual assessment and quantitative angiography versus fractional flow reserve for native coronary narrowings of moderate severity. Am J Cardiol 90 3 (2002) 210-215
12. Barbato E., Bartunek J., Aarnoudse W., et al. Alpha-adrenergic receptor blockade and hyperaemic response in patients with intermediate coronary stenoses. Eur Heart J 25 22 (2004) 2034-2039
13. Barbato E., Piscione F., Bartunek J., et al. Role of β2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation 111 (2005) 288-294
14. Barbato E., Aarnoudse W., Aengevaeren W.R., et al. Week 25 study group Validation of coronary flow reserve measurements by thermodilution in clinical practice. Eur Heart J 25 (2004) 219-223
15. Altman D.G. Practical statistics for medical research (1991), Chapman & Hall, London, UK
16. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
17. Akimoto K., Miyata A., Kangawa K., et al. Molecular forms of atrial natriuretic peptide in the atrium of patients with cardiovascular disease. J Clin Endocrinol Metab 67 (1988) 93-97
18. Miyata A., Kangawa k, Toshimori T., Hatoh T., and Matsuo H. Molecular forms of atrial natriuretic polypeptides in mammalian tissues and plasma. Biochem Biophys Res Commun 129 (1985) 248-255
19. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1411
20. Hosoda K., Nakao K., Mukoyama M., et al. Expression of brain natriuretic peptide gene in human heart Production in the ventricle. Hypertension 17 (1991) 1152-1155
21. Drewett J.G., and Garbers D.L. The family of guanylyl cyclase receptors and their ligands. Endocr Rev 15 (1994) 135-162
22. de Bold A., Bruneau B., and Kuroski de Bold M. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31 (1996) 7-18
23. Volpe M., Mele A.F., Indolfi C., et al. Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. J Am Coll Cardiol 10 (1987) 787
24. Volpe M., De Luca N., Cappelli Bigazzi M., et al. Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man. Circulation 77 4 (1988) 849-855
25. Rosenkranz A.C., Hood S.G., Woods R.L., Dusting G.J., and Ritchie R.H. B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP. Diabetes 52 (2003) 2389-2395
26. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
27. Kikuta K., Yasue H., Yoshimura M., et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 132 (1996) 101-107
28. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
29. Arad M., Elazar E., Shotan A., Klein R., and Rabinowitz B. Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure?. Cardiology 87 (1996) 12-17
30. Vanderheyden M., Bartunek J., Claeys G., et al. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 39 6 (2006) 640-645
31. Nishikimi T., Mori Y., Ishimura K., et al. Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. Am J Med 116 (2004) 517-523
32. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
33. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 (2004) 1988-1995
34. Bibbins-Domingo K., Ansari M., Sciller N.B., Massy B., and Whooley M.A. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the heart and soul study. Circulation 108 (2003) 2987-2992
35. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 25 (2006) 2631-2639
36. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
37. Foote R.S., Pearlman J.D., Siegel A.H., and Yeo K.T. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 44 (2004) 1980-1987
38. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
39. de Bold A.J., and Bruneau B.G. Natriuretic peptides. In: Fray J.C. (Ed). Handbook of physiology. Section 7, Volume III (2000), Oxford University Press, Oxford 377-409
40. de Bold A.J., Ma K.K., Zhang Y., et al. The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 79 (2001) 705-714
41. Hashimoto Y., Nakao K., Hama N., et al. Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm Res 11 (1994) 60-64
42. Heublein D.M., Clavell A.L., Stingo A.J., et al. C-type natriuretic peptide immunoreactivity in human breast vascular endothelial cells. Peptides 13 (1992) 1017-1019
43. Sudoh T., Minamino N., Kangawa K., and Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 168 (1990) 863-870
44. Igaki T., Itoh H., Suga S.I., et al. Effects of intravenously administered C-type natriuretic peptide in humans: comparison with atrial natriuretic peptide. Hypertens Res 21 (1998) 7-13
45. Barletta G., Lazzeri C., Vecchiarino S., et al. Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension 31 (1998) 802-808
46. Charles C.J., Espiner E.A., Richards A.M., Nicholls M.G., and Yandle T.G. Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. Am J Physiol Regul Integr Comp Physiol 268 (1995) R201-R207
47. Charles C.J., Espiner E.A., Richards A.M., Nicholls M.G., and Yandle T.G. Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. Am J Physiol Regul Integr Comp Physiol 270 (1996) R1324-R1331
48. Pham I., Sediame S., Maistre G., et al. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol Regul Integr Comp Physiol 273 (1997) R1457-R1464
49. Schmitt M., Qasem A., McEniery C., et al. Role of natriuretic peptides in regulation of conduit artery distensibility. Am J Physiol Heart Circ Physiol 287 (2004) H1167-H1171